This technology is a topical hydrogel/cream containing genetically engineered yeast that continuously secretes human CXCL12 and EGF to speed up wound healing and reduce complications.

This technology is a therapeutic strategy for neurodegenerative diseases involving the inhibition of the RhoA signaling pathway with small molecules and shRNA viral vectors to correct disrupted retromer-dependent endosome trafficking.

This technology is a gene-based therapy that targets the RhoA signaling pathway to treat metabolic dysfunction-associated steatohepatitis (MASH).